This listing of claims will replace all prior versions, and listings, of claims in the application:

## **Listing of Claims:**

Claim 1. (Currently Amended) A pharmaceutical preparation consisting of comprising active compound, gelatin as a binder and fillers and which is free of organic solvent residues, wherein the active compound is levo-thyroxine sodium, and which preparation is in tablet form.

Claim 2. (Canceled)

Claim 3. (**Previously Presented**) The pharmaceutical preparation according to claim 1, containing 5 to 400 µg of levothyroxine.

Claim 4. (**Previously Presented**) The pharmaceutical preparation according to claim 1, containing levothyroxine sodium micronized with a particle size of between 5  $\mu$ m and 25  $\mu$ m.

Claim 5. (**Previously Presented**) The pharmaceutical preparation according to Claim 1, wherein the filler is lactose, maize starch or microcrystalline cellulose.

Claim 6. (**Previously Presented**) The pharmaceutical preparation according to Claim 1, which is a solid preparation in the form of tablets.

Claim 7. (Canceled)

Claim 8. (Canceled)

- Claim 9. (**Currently Amended**) A pharmaceutical preparation <del>consisting</del> essentially of <u>comprising</u> levo-thyroxine sodium, gelatin as a binder and fillers which is free of organic solvent residues and which is in solid form.
- Claim 10. (**Currently Amended**) A pharmaceutical preparation comprising active compound, gelatin as a binder and fillers and which is free of organic solvent residues, wherein the active compound consists essentially of levo-thyroxine sodium and liothyronine sodium, and which preparation is in solid form.
- Claim 11. (**Previously Presented**) The pharmaceutical preparation according to claim 9, containing 5 to 400 µg of levothyroxine.
- Claim 12. (**Previously Presented**) The pharmaceutical preparation according to claim 9, containing levothyroxine sodium micronized with a particle size of between 5  $\mu$ m and 25  $\mu$ m.
- Claim 13. (**Previously Presented**) The pharmaceutical preparation according to claim 9, wherein the filler is lactose, maize starch or microcrystalline cellulose.
- Claim 14. (**Previously Presented**) The pharmaceutical preparation according to claim 10, containing 5 to 400 µg of levothyroxine.
- Claim 15. (**Previously Presented**) The pharmaceutical preparation according to claim 10, containing levothyroxine sodium micronized with a particle size of between 5  $\mu$ m and 25  $\mu$ m.
- Claim 16 (**Previously Presented**) The pharmaceutical preparation according to claim 10, wherein the filler is lactose, maize starch or microcrystalline cellulose.